Response of leptomeningeal metastases from breast cancer to hormonal therapy
- 12 July 2000
- journal article
- case report
- Published by Wolters Kluwer Health in Neurology
- Vol. 55 (1) , 117-119
- https://doi.org/10.1212/wnl.55.1.117
Abstract
Article abstract Intraventricular chemotherapy with radiotherapy is the standard treatment of leptomeningeal metastasis (LM) from breast cancer; this treatment increases median survival only to about 3 months and is frequently complicated by serious side effects. The authors describe two patients with LM from breast cancer who were treated with hormonal therapy, which provided a neurologic response of at least 12 months and a survival of 14+ and 19 months. Hormonal therapy can be effective and nontoxic for patients with LM from breast cancer.Keywords
This publication has 10 references indexed in Scilit:
- Leptomeningeal metastases from solid tumorsCancer, 1998
- Leptomeningeal metastases: A review of evaluation and treatmentJournal of Neuro-Oncology, 1998
- Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.Journal of Clinical Oncology, 1993
- Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patientsBritish Journal of Cancer, 1991
- Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatmentCancer, 1991
- Meningeal carcinomatosis from breast cancer: Spinal cord vs. brain involvementBreast Cancer Research and Treatment, 1987
- Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosisJournal of Neuro-Oncology, 1987
- Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patientsCancer, 1982
- Meningeal carcinomatosis in breast cancerCancer, 1978
- Meningeal CarcinomatosisArchives of Neurology, 1974